Kiyatec strengthens its leadership position with the addition of Mark Capone, former CEO of Myriad Genetics as Strategic Advisor.

Kiyatec, a leading functional precision oncology company specializing in 3D cell culture technology and delivering evidence of therapeutic response in the oncology space, is pleased to announce that Mark Capone,…

Continue ReadingKiyatec strengthens its leadership position with the addition of Mark Capone, former CEO of Myriad Genetics as Strategic Advisor.

Kiyatec Appoints Eric Perreault to President and Appoints Tessa DesRochers, PhD, Chief Scientific Officer to Vice President of Pre-Clinical Services

August 01, 2023 10:00 AM Eastern Daylight Time GREENVILLE, S.C.--(BUSINESS WIRE)--Kiyatec, a leading biotechnology company specializing in 3D cell culture technologies, is pleased to announce the appointment of Eric Perreault to…

Continue ReadingKiyatec Appoints Eric Perreault to President and Appoints Tessa DesRochers, PhD, Chief Scientific Officer to Vice President of Pre-Clinical Services

Kiyatec and XenoSTART formally announce a collaborative agreement to help reduce drug development costs by providing correlative ex vivo efficacy data using Kiyatec’s 3D spheroid screening platform, KIYA-PredictTM

June 27th, 2023 – GREENVILLE, S.C. - Kiyatec, the leader in clinically correlated functional precision oncology, and XenoSTART, the worldwide leader in patient derived xenograft model development, have formally announced their ongoing collaboration…

Continue ReadingKiyatec and XenoSTART formally announce a collaborative agreement to help reduce drug development costs by providing correlative ex vivo efficacy data using Kiyatec’s 3D spheroid screening platform, KIYA-PredictTM

Kiyatec and AstraZeneca Announce a Multifaceted Research Agreement to Generate Novel Preclinical Data Using Kiyatec’s 3D Spheroid Screening Platform, KIYA-PredictTM

May 23rd, 2023 – GREENVILLE, S.C. - AstraZeneca and Kiyatec, the leader in clinically correlated functional precision oncology, have entered into a multifaceted research agreement to assess therapeutic efficacy of undisclosed preclinical…

Continue ReadingKiyatec and AstraZeneca Announce a Multifaceted Research Agreement to Generate Novel Preclinical Data Using Kiyatec’s 3D Spheroid Screening Platform, KIYA-PredictTM

Kiyatec Announces Investment from Leading Brain Cancer Venture Philanthropy Funds

GREENVILLE, S.C. — Kiyatec, Inc., the leader in functional precision oncology, today announced a new investment from the venture philanthropy arms of two leading brain tumor patient organizations. The Brain Tumor Investment Fund, an…

Continue ReadingKiyatec Announces Investment from Leading Brain Cancer Venture Philanthropy Funds

Kiyatec to present two posters highlighting the company’s work in ex vivo immuno-oncology at the 2023 AACR Annual Meeting April 14-19, in Orlando, FL

GREENVILLE, S.C.-- Kiyatec, the leader in clinically correlated, published functional precision oncology technology, today announced that two abstracts were accepted for poster presentations at the American Association for Cancer Research…

Continue ReadingKiyatec to present two posters highlighting the company’s work in ex vivo immuno-oncology at the 2023 AACR Annual Meeting April 14-19, in Orlando, FL

Functional precision oncology leader Kiyatec announces Series C round with US$18 million closing to accelerate adoption of transformational cancer platform

Company is positioned to scale predictive platform’s impact in cancer patient therapy selection and preclinical pharma services. DECEMBER 12, 2022 – Greenville SC -- Kiyatec Inc. announced today a closing…

Continue ReadingFunctional precision oncology leader Kiyatec announces Series C round with US$18 million closing to accelerate adoption of transformational cancer platform

Unique Partnership Seeks to Advance Precision Medicine Options for Deadly GBM Brain Tumors

Unique Partnership Seeks to Advance Precision Medicine Options for Deadly GBM Brain Tumors Shared goal is using high quality live-cell tissue to achieve patient-specific treatment, improved patient outcomes INDIANAPOLIS (October…

Continue ReadingUnique Partnership Seeks to Advance Precision Medicine Options for Deadly GBM Brain Tumors

Kiyatec to Sponsor and Exhibit at the Virtual American Brain Tumor Association 2022 National Conference September 9-10, 2022

September 07, 2022 08:00 AM Eastern Daylight Time GREENVILLE, S.C.--(BUSINESS WIRE)--Kiyatec, the leader in clinically correlated, published functional precision oncology evidence today announced the company is sponsoring and exhibiting at…

Continue ReadingKiyatec to Sponsor and Exhibit at the Virtual American Brain Tumor Association 2022 National Conference September 9-10, 2022